摘要
目的探讨华蟾素联合注射用洛铂TACE治疗在中晚期肝癌治疗中的临床疗效和安全性。方法将36例肝癌患者随机分为2组,治疗组(华蟾素注射液联合洛铂TACE)18例,对照组(单纯洛铂TACE)18例,观察患者治疗前后瘤体变化和VEGF等指标变化。结果联合治疗组和对照组有效率分别为72%和50%(P<0.05),治疗后联合治疗组与对照组血清血管内皮生长因子(VEGF)和乏氧诱导因子(HIF)-1a水平差异具有统计学意义(P<0.05)。结论华蟾素注射液联合TACE治疗中晚期肝癌能较好地抑制栓塞后局部微环境乏氧诱导细胞和肿瘤血管生成因子,从而抑制TACE后残余肿瘤复发转移。
Objective To study the effect and safety of transcatheter arterial embolization with Cinobufacini and Lobaplatin for injection on terminal stage of Hepatocellular Carcinoma .Methods The 36 patients were randomly divide into two groups ,18 patients in treatment group （Cinobufacini and Lobaplatin for injection ） while 18 patients in control group （Lobaplatin only ） ,the change of carcinoma and VEGF were recorded .Results The effective rate of treatment group was 72% ,while control group was 50% （ P〈0 .05 ） .Hypoxia-inducible factor and Vascular endothelial of he two groups had ob-viously contracted with statistical difference （ P〈0 .05 ） .Conclusion Transcatheter arterial embolization with Cinobufacini and Lobaplatin for injection on terminal stage of Hepatocellular Carcinoma can decrease Hypoxia-inducible factor Vascular endothelial ,and thereby inhabit metastases and recrudesce of the carcinoma .
出处
《吉林中医药》
2015年第7期678-680,共3页
Jilin Journal of Chinese Medicine
基金
南京市医学科技发展重点项目(ZKX13018)
江苏省中医药领军人才项目(LJ200922)
江苏省"333高层次人才培养工程"项目(苏人才〔2011〕15号)
关键词
肝细胞癌
华蟾素注射液
肝动脉化疗栓塞术
血管内皮生长因子
乏氧诱导因子
hepatocellular carcinoma
cinobufacini injection
transcatheter arterial embolization
vascular endothelial growth factor
hypoxia-inducible factor
